Мышечно-неинвазивный рак мочевого пузыря: современный взгляд на биомаркеры

Мышечно-неинвазивный рак мочевого пузыря: современный взгляд на биомаркеры

Автор: Солодкий В.А., Павлов А.Ю., Дзидзария А.Г., Гафанов Р.А., Абдирахимов Л.А., Боженко В.К., Цаллагова З.С.

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Рубрика: Обзоры, лекции

Статья в выпуске: 3 т.22, 2022 года.

Бесплатный доступ

Алгоритм принятия терапевтических решений для лечения больных с мышечно- неинвазивным рак мочевого пузыря (МНИРМП) по-прежнему является проблемой в клинической практике, поскольку прогностические биомаркеры ответа на лечение все еще находятся в стадии изучения. В дополнение к факторам риска, определенным EORTC, гистологические особенности также являются ключевыми переменными, способными повлиять на рецидив и прогрессирование рака мочевого пузыря. Как и мышечно-инвазивный рак, МНИРМП является гетерогенным заболеванием, характеризующимся геномной нестабильностью, различной скоростью мутаций и широким диапазоном экспрессии белков в тканях. В этом обзоре мы обобщили последние данные о прогностических и прогностически значимых тканевых биомаркерах при МНИРМП, помимо морфологических параметров, в плане их влияния на биологию опухоли и, следовательно, на ее поведение во время лечения. В обзоре приведены данные о наиболее распространенных молекулярных событиях, связанных с рецидивом и прогрессированием, а также обсуждена связь между доступными методами лечения и молекулярными факторами, которые могут предсказывать клинический ответ.

Еще

Прогностический, биомаркер, мышечно-неинвазивный рак мочевого пузыря, рак мочевого пузыря, молекулярные подтипы, реакция бцж

Короткий адрес: https://sciup.org/149142270

IDR: 149142270

Список литературы Мышечно-неинвазивный рак мочевого пузыря: современный взгляд на биомаркеры

  • Kulkarni G.S., Hakenberg G.S., Gschwend O.W., et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol. 2010. V. 57. No.1. P. 60-70. DOI: 10.1016/j.eururo.2009.08.024
  • Babjuk M., Bohle A., Burger M., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016. Eur Urol. 2017. V. 71. No. 3. P. 447-461. DOI: 10.1016/j.eururo.2016.05.041.
  • Hedegaard J., Lamy P., Nordentoft I., et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell. 2016. V. 30. No. 1. P. 27-42. DOI: 10.1016/j.ccell.2016.05.004.
  • Du J., Wang S.H., Yang Q., et al. p53 status correlates with the risk of progression in stage T1 bladder cancer: A meta-analysis. World J Surg Oncol. 2016. V. 14. No. 1. Article ID 137. DOI: 10.1186/s12957-016-0890-9.
  • D'Andrea D., Hassler M.R., Abufaraj M., et al. Progressive tissue biomarker profiling in non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2018. V. 18. No. 7. P. 695-703. DOI: 10.1080/ 14737140.2018.1474104.
  • Bruchbacher A., Soria F., Hassler M., et al. Tissue biomarkers in nonmuscle-invasive bladder cancer: Any role in clinical practice? Curr Opin Urol. 2018. V. 28. No. 6. P. 584-590. DOI: 10.1097/MOU.0000000000000546.
  • Sarkis A.S., Dalbagni G., Cordon-Cardo C., et al. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol. 1994. V. 152. No. 2. P. 388392. DOI: 10.1016/ S0022-5347(17)32745-3.
  • Sarkis A.S., Zhang Z., Cordoncardo C., et al. p53 nuclear overexpression and disease progression in Ta bladder carcinoma. Int J Oncol. 1993. V. 3. No. 2. P. 355-360. DOI: 10.3892/ijo.3.2.355.
  • Shariat S.F., Weizer A.Z., Green A., et al. Prognostic value of p53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology. 2000. V. 56. No. 5. P. 735-740. DOI: 10.1016/S0090-4295(00)00756-1.
  • Santos L., Amaro T., Costa C., et al. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification. Int J Cancer. 2003. V. 105. No. 2. P. 267-272. DOI: 10.1002/ijc.11049.
  • Shariat S.F., Zlotta A.R., Ashfaq R., et al. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol. 2007. V. 20. No. 4. P. 445-459. DOI: 10.1038/modpathol.3800757.
  • Shariat S.F., Chade D.C., Karakiewicz P.I., et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol. 2010. V. 183. V. 1. P. 68-75. DOI: 10.1016/j.juro.2009.08.115.
  • Shariat S.F., Ashfaq R., Sagalowsky A.I., Lotan Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol. 2007. V. 177. No. 2. P. 481487. DOI: 10.1016/j.juro.2006.09.038.
  • Liukkonen T., Rajala P., Raitanen M., et al. Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/T1) bladder cancer: A prospective comparative study. Eur Urol. 1999. V. 36. No. 5. P. 393-400. DOI: 10.1159/000020039.
  • Lopez-Beltran A., Luque R.J., Alvarez-Kindelan J., et al. Prognostic factors in stage T1 grade 3 bladder cancer survival: The role of G1-s modulators (p53, p21Waf1, p27kip1, cyclin D1, and cyclin D3) and proliferation index (ki67-MIB1). Eur Urol. 2004. V. 45. No. 5. P. 606-612. DOI: 10.1016/ j.eururo.2003.11.011.
  • Passoni N., Gayed B., Kapur P., et al. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer. Urol Oncol Semin Orig Investig. 2016. V. 34. No. 11. P. 485e7-\-485.e14. DOI: 10.1016/ j.urolonc.2016.05.014.
  • Passoni N.M., Shariat S.F., Bagrodia A., et al. Concordance in biomarker status between bladder tumors at time of transurethral resection and subsequent radical cystectomy: Results of a 5-year prospective study. Bladder Cancer. 2016. V. 2. No. 1. P. 91-99. DOI: 10.3233/BLC-150036.
  • Ko K., Jeong C.W., Kwak C., et al. Significance of ki-67 in non- muscle invasive bladder cancer patients: a systematic review and meta-analysis. Oncotarget. 2017. V. 8. No. 59. P. 100614-100630. DOI: 10.18632/oncotarget.21899.
  • Culpan M., Turan T., Ozkanli S.S., et al. Prognostic and clinicopathologic value of ki-67 and profilin 1 immunohistochemical expression in primary pT1 urothelial bladder cancer. J Cancer Res Ther. 2021. V. 17. No. 2. P. 434-442. DOI: 10.4103/jcrt.JCRT_408_19.
  • Harsanyi S., Ziaran S., Bevizova K., et al. The prognostic value of e-cadherin and ki-67 compared to standard histopathologic examination in non-muscle invasive bladder cancer. Bratisl Med J. 2020. V. 121. No. 6. P. 444-449. DOI: 10.4149/BLL_2020_072.
  • Lillesand M., Kvikstad V., Mangrud O.M., et al. Mitotic activity index and CD25+ lymphocytes predict risk of stage progression in non-muscle invasive bladder cancer. PLoS One. 2020. V. 15. No. 6. Article ID e0233676. DOI: 10.1371/journal.pone.0233676.
  • Hernandez S., Lôpez-Knowles E., Lloreta J., et al. FGFR3 and Tp53 mutations inT1G3 transitional bladder carcinomas: Independent distribution and lack of association with prognosis. Clin Cancer Res. 2005. V. 11. No. 15. P. 5444-5450. DOI: 10.1158/1078-0432.CCR-05-0122.
  • Hernández S., López-Knowles E., Lloreta J., et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 2006. V. 24. No. 22. P. 3664-3671. DOI: 10.1200/jc0.2005.05.1771.
  • Pouessel D., Neuzillet Y., Mertens L.S., et al. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: Implications for perioperative anti-FGFR3 treatment. Ann Oncol. 2016. V. 27. No. 7. P. 1311-1316. DOI: 10.1093/annonc/mdw170.
  • Wolff A.C., M Hammond E.H., Hicks D.G., et al. Recommendation for HER2 testing in breast cancer. NIH Public Access Author Manuscr. 2014. V. 23. No. 1. P. 1-7. DOI: 10.5858/arpa.2013-0953-SA.Recommendations.
  • Kunz P.L., Mojtahed A., Fisher G.A., et al. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: Clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol. 2012. V. 20. No. 1. P. 13-24. DOI: 10.1097/PAI.0b013e31821c821c.
  • Joensuu H., Kellokumpu-Lehtinen P-L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast. N Engl J Med. 2006. V. 354. No. 8. P. 809-820. DOI: 10.1056/NEJMoa053028.
  • Olsson H., Fyhr I.M., Hultman P., Jahnson S. HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder. Scand J Urol Nephrol. 2012. V. 46. No. 2. P. 102-107. DOI: 10.3109/00365599.2011.637955.
  • Chen P.C.H., Yu H.J., Chang Y.H., Pan C.C. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression. J Clin Pathol. 2013. V. 66. No. 2. P. 113-119. DOI: 10.1136/jclinpath-2012-200944.
  • Lim S.D., Cho Y.M., Choi G.S., et al. Clinical significance of substaging and her2 expression in papillary nonmuscle invasive urothelial cancers of the urinary bladder. J Korean Med Sci. 2015. V. 30. No. 8. P. 1068-1077. DOI: 10.3346/jkms.2015.30.8.1068.
  • Breyer J., Wirtz R.M., Otto W., et al. Predictive value of molecular subtyping in MHHPMn by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies. Oncotarget. 2017. V. 8. No. 40. P. 67684-67695. DOI: 10.18632/oncotarget.18804.
  • Sanguedolce F., Cormio A., Massenio P., et al. Altered expression of HER-2 and the mismatch repair genes MLH1 and MSH2 predicts the outcome of T1 high-grade bladder cancer. J Cancer Res Clin Oncol. 2018. V. 144. No. 4. P. 637-644. DOI: 10.1007/s00432-018-2593-9.
  • Bryan R.T, Tselepis C. Cadherin switching and bladder cancer. J Urol. 2010. V. 184. No. 2. P. 423-431. DOI: 10.1016/j.juro.2010.04.016.
  • Wang P., Lin S.L., Zhang L.H., et al. The prognostic value of p-cadherin in non-muscle-invasive bladder cancer. Eur J Surg Oncol. 2014. V. 40. No. 3. P. 255-259. DOI: 10.1016/j.ejso.2013.12.018.
  • AbufarajM., Shariat S.F., Haitel A., et al. Prognostic role of n-cadherin expression in patients with non-muscle-invasive bladder cancer. Urol Oncol Semin Orig Investig. 2017. V. 35. No. 5. P. 264-271. DOI: 10.1016/ j.urolonc.2017.01.012.
  • Liu B., Miyake H., Nishikawa M., Fujisawa M. Expression profile of epithelial- mesenchymal transition markers in non-muscle-invasive urothelial carcinoma of the bladder: Correlation with intravesical recurrence following transurethral resection. Urol Oncol Semin Orig Investig. 2015. V. 33. No. 3. P. 110e11-110e18. DOI: 10.1016/j.urolonc.2014.08.012.
  • Otto W., Breyer J., Herdegen S., et al. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant e-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach. Int Urol Nephrol. 2017. V. 49. No. 3. P. 431-437. DOI: 10.1007/s11255-016-1491-9.
  • Ambrosini DCAG, Adida C, Sirugo G. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem. 1998. V. 273. No. 18. P. 11177-11182. DOI: 10.1074/jbc.273.18.11177.
  • Ambrosini G., Colette A., Altieri D. A nover anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997. V. 3. No. 8. P. 917-921. DOI: 10.1038/ nm0897-917.
  • Schultz I.J., Witjes J.A., Swinkels D.W., de Kok J.B. Bladder cancer diagnosis and recurrence prognosis: Comparison of markers with emphasis on survivin. Clin Chim Acta. 2006. V. 368. No. 1-2. P. 20-32. DOI: 10.1016/j.cca.2005.12.036.
  • Shariat S.F., Ashfaq R., Karakiewicz P.I., et al. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer. 2007. V. 109. No. 6. P. 1106-1113. DOI: 10.1002/cncr.22521.
  • Karam J.A., Lotan Y., Ashfaq R., et at. Survivin expression in patients with non-Muscle-Invasive urothelial cell carcinoma of the bladder. Urology. 2007. V. 70. No. 3. P. 482-486. DOI: 10.1016/j.urology.2007.05.009.
  • Scosyrev E., Noyes K., Feng C., Messing E. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer. 2009. V. 115. 1. P. 68-74. DOI: 10.1002/cncr.23986.
  • Burge F., Kockelbergh R. Closing the gender gap: Can we improve bladder cancer survival in women? - a systematic review of diagnosis, treatment and outcomes. Urol Int. 2016. V. 97. No. 4. P. 373-379. DOI: 10.1159/000449256.
  • Miyamoto H., Yang Z., Chen Y.T., et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst. 2007. V. 99. No. 7. P. 558-568. DOI: 10.1093/jnci/djk113.
  • Hsu J.W., Hsu I., Xu D., et al. Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor. Am J Pathol. 2013. V. 182. No. 5. P. 1811-1820. DOI: 10.1016/ j.ajpath.2013.01.018.
  • Imada S., Akaza H., Ami Y., et al. Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. Eur Urol. 1997. V. 31. No. 3. P. 360-364. DOI: 10.1159/000474484.
  • Lin C., Yin Y., Stemler K., et al. Constitutive b-catenin activation induces male-specific tumorigenesis in the bladder urothelium. Cancer Res. 2013. V. 73. No. 19. P. 5914-5925. DOI: 10.1158/0008- 5472.CAN-12-4198.
  • Izumi K., Taguri M., Miyamoto H., et al. Androgen deprivation therapy prevents bladder cancer recurrence. Oncotarget. 2014. V. 5. No. 24. P. 12665-12674. DOI: 10.18632/oncotarget.2851.
  • Zheng Y., Izumi K., Yao J.L., Miyamoto H. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. Endocr Relat Cancer. 2011. V. 18. No. 4. P. 451-464. DOI: 10.1530/ERC-11-0010.
  • Mashhadi R., Pourmand G., Kosari F., et al. Role of steroid hormone receptors in formation and progression of bladder carcinoma: A case-control study. Urol J. 2014. V. 11. No. 6. P. 1968-1973.
  • Boorjian S., Ugras S., Mongan N.P., et al. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology. 2004. V. 64. No. 2. P. 383388. DOI: 10.1016/j.urology.2004.03.025.
  • Tuygun C., Kankaya D., Imamoglu A., et al. Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: A comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol Semin Orig Investig. 2011. V. 29. No. 1. P. 43-51. DOI: 10.1016/j.urolonc.2009.01.033.
  • Sikic D., Breyer J., Hartmann A., et al. High androgen receptor mRNA expression is independently associated with prolonged cancer-specific and recurrence-free survival in stage T1 bladder cancer. Transl Oncol. 2017. V. 10. No. 3. P. 340-345. DOI: 10.1016/j.tranon.2017.01.013.
  • Yasui M., Kawahara T., Izumi K., et al. Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer. BMC Cancer. 2019. V. 19. No. 1. P. 1-6. DOI: 10.1186/ s12885-019-5512-9.
  • Krpina K., Babarovic E., JonjicN. Correlation of tumor-infiltrating lymphocytes with bladder cancer recurrence in patients with solitary low-grade urothelial carcinoma. Virchows Arch. 2015. V. 467. No. 4. P. 443-438. DOI: 10.1007/s00428- 015-1808-6.
  • Bostrom M.M., Irjala H., Mirtti T., et al. Tumor- associated macrophages provide significant prognostic information in urothelial bladder cancer. PLoS One. 2015. V. 10. No. 7. Article ID e0133552. DOI: 10.1371/ journal.pone.0133552.
  • Brandau S., Riemensberger J., Jacobsen M., et al. NK cells are essential for effective BCG immunotherapy. Int J Cancer. 2001. V. 92. No. 5. P. 697-702. DOI: 10.1002/1097-0215(20010601)92:5<697:aid-ijc1245-3.0.co;2-z..
  • Shariat S.F., Matsumoto K., Kim J., et al. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. J Urol. 2003. V. 170. No. 3. P. 985-589. DOI: 10.1097/01.ju.0000080401.85145.ee.
  • Margulis V., Shariat S.F., Ashfaq R., et al. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. J Urol. 2007. V. 177. No. 3. P. 1163-1168. DOI: 10.1016/j.juro.2006.10.033.
  • Tadin T., Krpina K., Stifter S. Lower cyclooxygenase-2 expression is associated with recurrence of solitary non-muscle invasive bladder carcinoma. Diagn Pathol. 2012. V. 7. No. 1. Article ID 152. DOI: 10.1186/1746-1596- 7-152.
  • Breyer J., Wirtz R.M., Otto W., et al. High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (MHHPMn) patients. Cancer Immunol Immunother. 2018. V. 67. No. 3. P. 403-412. DOI: 10.1007/s00262-017-2093-9.
  • Ke H-L., Lin J., Ye Y., et al. Genetic variations in glutathione pathway genes predict cancer recurrence in patients treated with transurethral resection and bacillus calmette-guerin instillation for non-muscle invasive bladder cancer. Ann Surg Oncol. 2015. V. 22. No. 12. P. 4104-4110. DOI: 10.1245/ s10434-015-4431-5.
  • Gaya J.M., Lopez-Martinez J.M., Karni-Schmidt O., et al. DNp63 expression is a protective factor of progression in clinical high grade T1 bladder cancer. J Urol. 2015. V. 193. No. 4. P. 1144-1150. DOI: 10.1016/j.juro.2014.10.098.
  • Piao X-M., Kang H.W., Jeong P., et al. A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer. Urol Oncol. 2021. V. 39. No. 4. P. 237.e21-237.e29. DOI: 10.1016/j.urolonc.2020.11.017.
  • Taber A., Park Y., Lelo A., Prip F., et al. STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer. Urol Oncol. 2021. V. 39. No. 7. P. 438.e1-458e9. DOI: 10.1016/j.urolonc.2021.02.007.
  • Muilwijk T., Akand M., Daelemans S., et al. Stromal marker fibroblast activation protein drives outcome in T1 non- muscle invasive bladder cancer. PLoS One. 2021. V. 16. No. 9. Article ID e0257195. DOI: 10.1371/ journal.pone.0257195.
  • Piao X-M., You C., Byun Y.J., et al. Prognostic value of BUB1 for predicting non-Muscle-Invasive bladder cancer progression. Int J Mol Sci. 2021. V. 22. No. 23. Article ID 12756. DOI: 10.3390/ijms222312756.
  • Choi W., Porten S., Kim S., et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014. V. 25. No. 2. P. 152-165. DOI: 10.1016/j.ccr.2014.01.009.
  • Dadhania V., Zhang M., Zhang L., et al. Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine. 2016. V. 12. P. 105-117. DOI: 10.1016/j.ebiom.2016.08.036.
  • Rebola J., Aguiar P., Blanca A., et al. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype. Virchows Arch. 2019. V. 475. No. 4. P. 445-455. DOI: 10.1007/s00428-019-02593-x.
  • Breyer J., Wirtz R.M., Otto W., et al. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. Virchows Arch Int J Pathol. 2017. V. 470. No. 3. P. 267-274. DOI: 10.1007/s00428- 017-2064-8.
  • Dyrskj0t L., Reinert T., Algaba F., et al. Prognostic impact of a 12-gene progression score in non-muscle-invasive bladder cancer: A prospective multicentre validation study. Eur Urol. 2017. V. 72. No.3. P. 461-469. DOI: 10.1016/j.eururo.2017.05.040.
  • Balar A.V., Kamat A.M., Kulkarni G.S., et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle- invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021. V. 22. No. 7. P. 919930. DOI: 10.1016/S1470-2045(21)00147-9.
  • Black P.C., Tangen C., Singh P., et al. Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816). J Clin Oncol. 2021. V. 39. No. 15. Suppl. P. 4541-4541. DOI: 10.1200/Jœ.2021.39.15_suppl.4541.
  • Pierconti F., Raspollini M.R., Martini M., et al. PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders. Virchows Arch Int J Pathol. 2020. V. 477. No. 2. P. 269-277. DOI: 10.1007/s00428-020-02755-2.
  • Kates M., Nirschl T., Sopko N.A., et al. Intravesical BCG induces CD4+ T-cell expansion in an immune competent model of bladder cancer. Cancer Immunol Res. 2017. V. 5. No. 7. P. 594-603. DOI: 10.1158/2326- 6066.CIR-16-0267.
  • Kates M., Matoso A., Choi W., et al. Adaptive immune resistance to intravesical BCG in non-muscle invasive bladder cancer: Implications for prospective BCG-unresponsive trials. Clin Cancer Res Off J Am Assoc Cancer Res. 2020. V. 26. No. 4 P. 882-891. DOI: 10.1158/1078-0432.CCR-19-1920.
  • Boegemann M., Aydin A.M., Bagrodia A., Krabbe L-M.Prospects and progress of immunotherapy for bladder cancer. Expert Opin Biol Ther. 2017. V. 17. No. 11. P. 14171431. DOI: 10.1080/14712598.2017.1366445.
  • Pichler R., Gruenbacher G., Culig Z., et al. Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer. Cancer Immunol Immunother CII. 2017. V. 66. No. 4. P. 427-440. DOI: 10.1007/s00262-016-1945-z.
  • Goodman A.M., Kato S., Bazhenova L., et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017. V. 16. No. 11. P. 2598-2608. DOI: 10.1158/1535-7163.MCT-17-0386.
  • Gubin M.M., ZhangX., Schuster H., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014. V. 515. No. 7528. P. 577-581. DOI: 10.1038/nature13988.
  • Meeks J.J., Carneiro B.A., Pai S.G., et al. Genomic characterization of high-risk non-muscle invasive bladder cancer. Oncotarget. 2016. V. 7. No. 46. P. 75176-75184. DOI: 10.18632/oncotarget.12661.
  • Deng X., Yang X., Cheng Y., et al. GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy. Sci Rep. 2015. V. 5. Article ID 14000. DOI: 10.1038/srep14000.
  • Hahn N.M., Bivalacqua T.J., Ross A.E., et al. A phase II trial of dovitinib in BCG-unresponsive urothelial carcinoma with FGFR3 mutations or overexpression: Hoosier cancer research network trial HCRN 12-157. Clin Cancer Res Off J Am Assoc Cancer Res. 2017. V. 23. No. 12. P. 3003-3011. DOI: 10.1158/ 1078-0432.CCR-16-2267.
Еще
Статья научная
SciUp 2024 © 2024 ©